Insider Selling: Neuronetics (NASDAQ:STIM) EVP Sells $22,017.54 in Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP Steven Pfanstiel sold 16,431 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $1.34, for a total value of $22,017.54. Following the transaction, the executive vice president directly owned 828,781 shares in the company, valued at $1,110,566.54. This trade represents a 1.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neuronetics Price Performance

Shares of STIM stock opened at $1.29 on Friday. The stock has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.96. The company has a quick ratio of 1.87, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. The firm has a market cap of $89.37 million, a price-to-earnings ratio of -2.19 and a beta of 0.87. Neuronetics, Inc. has a 12 month low of $0.80 and a 12 month high of $4.85.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The firm had revenue of $41.78 million during the quarter, compared to analysts’ expectations of $40.84 million. Research analysts expect that Neuronetics, Inc. will post -1.13 EPS for the current year.

Hedge Funds Weigh In On Neuronetics

Several institutional investors have recently modified their holdings of the stock. Presidio Capital Management LLC bought a new stake in shares of Neuronetics in the 3rd quarter valued at about $32,000. Intrua Financial LLC bought a new position in Neuronetics during the 3rd quarter worth approximately $33,000. Sherbrooke Park Advisers LLC bought a new position in Neuronetics during the 3rd quarter worth approximately $33,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Neuronetics during the second quarter valued at approximately $34,000. Finally, Raymond James Financial Inc. acquired a new position in Neuronetics during the second quarter valued at approximately $37,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on STIM. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a report on Thursday, January 22nd. Canaccord Genuity Group lowered their target price on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, March 19th. Finally, Wall Street Zen downgraded Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.